scholarly journals Clinical Utility of Tumor Markers

2021 ◽  
Vol 11 (02) ◽  
pp. 38-57
Author(s):  
Taro Mizuno ◽  
Takayuki Goto ◽  
Kota Shimojo ◽  
Naoki Watanabe ◽  
Takuji Tanaka
Keyword(s):  
Tumor Markers ◽  
Clinical Utility

scholarly journals Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting

2012 ◽  
Vol 30 (34) ◽  
pp. 4223-4232 ◽  
Author(s):  
Lisa M. McShane ◽  
Daniel F. Hayes
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Comparative Effectiveness Research ◽  
Comparative Effectiveness ◽  
Clinical Utility ◽  
The Body ◽  
Selective Reporting ◽  
Effectiveness Research ◽  
Study Quality ◽  
Transparent Reporting

Clinical management decisions for patients with cancer are increasingly being guided by prognostic and predictive markers. Use of these markers should be based on a sufficiently comprehensive body of unbiased evidence to establish that benefits to patients outweigh harms and to justify expenditure of health care dollars. Careful assessments of the clinical utility of markers by using comparative effectiveness research methods are urgently needed to more rigorously summarize and evaluate the evidence, but multiple factors have made such assessments difficult. The literature on tumor markers is plagued by nonpublication bias, selective reporting, and incomplete reporting. Several measures to address these problems are discussed, including development of a tumor marker study registry, greater attention to assay analytic performance and specimen quality, use of more rigorous study designs and analysis plans to establish clinical utility, and adherence to higher standards for reporting tumor marker studies. More complete and transparent reporting by adhering to criteria such as BRISQ [Biospecimen Reporting for Improved Study Quality] criteria for reporting details about specimens and REMARK [Reporting Recommendations for Tumor Marker Prognostic Studies] criteria for reporting a multitude of aspects relating to study design, analysis, and results, is essential for reliable assessment of study quality, detection of potential biases, and proper interpretation of study findings. Adopting these measures will improve the quality of the body of evidence available for comparative effectiveness research and enhance the ability to establish the clinical utility of prognostic and predictive tumor markers.

Clinical utility of serum tumor markers and cytokines in cervical cancer and neoplasia

2013 ◽  
Vol 0 (0) ◽  
pp. 1-4
Author(s):  
Li Juan ◽  
Hong-li Tong ◽  
Peng-jun Zhang ◽  
Xin-yu Wen ◽  
Yan-hong Gao ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Tumor Markers ◽  
Clinical Utility ◽  
Serum Tumor Markers

scholarly journals Clinical utility of tumor markers

2006 ◽  
Vol 25 (2) ◽  
pp. 119-125
Author(s):  
Svetlana Ignjatovic
Keyword(s):  
Tumor Markers ◽  
Clinical Utility

scholarly journals Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung

2020 ◽  
Author(s):  
Caiyue Ren ◽  
Jianping Zhang ◽  
Ming Qi ◽  
Jiangang Zhang ◽  
Yingjian Zhang ◽  
...  
Keyword(s):  
Machine Learning ◽  
Squamous Cell Carcinoma ◽  
Tumor Markers ◽  
Clinical Utility ◽  
Prediction Models ◽  
Clinical Factors ◽  
Combined Model ◽  
Biological Features ◽  
Pet Ct ◽  
Predictive Efficiency

Abstract Purpose To develop and validate a clinico-biological features and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) radiomic-based nomogram via machine learning for the pretherapy prediction of discriminating between adenocarcinoma (ADC) and squamous cell carcinoma (SCC) in non-small cell lung cancer (NSCLC). Methods A total of 315 NSCLC patients confirmed by postoperative pathology between January 2017 and June 2019 were retrospectively analyzed and randomly divided into the training (n = 220) and validation (n = 95) sets. Preoperative clinical factors, serum tumor markers, and PET, and CT radiomic features were analyzed. Prediction models were developed using the least absolute shrinkage and selection operator (LASSO) regression analysis. The performance of the models was evaluated and compared by the area under receiver-operator characteristic (ROC) curve (AUC) and DeLong test. The clinical utility of the models was determined via decision curve analysis (DCA). Then, a nomogram was developed based on the model with the best predictive efficiency and clinical utility and was validated using the calibration plots. Results In total, 122 SCC and 193 ADC patients were enrolled in this study. Four independent prediction models were separately developed to differentiate SCC from ADC using clinical factors-tumor markers, PET radiomics, CT radiomics, and their combination. The DeLong test and DCA showed that the Combined Model, consisting of 2 clinical factors, 2 tumor markers, 7 PET radiomics, and 3 CT radiomic parameters, held the highest predictive efficiency and clinical utility in predicting the NSCLC subtypes compared with the use of these parameters alone in both the training and validation sets (AUCs (95% CIs) = 0.932 (0.900–0.964), 0.901 (0.840–0.957), respectively) (p < 0.05). A quantitative nomogram was subsequently constructed using the independently risk factors from the Combined Model. The calibration curves indicated a good consistency between the actual observations and nomogram predictions. Conclusion This study presents an integrated clinico-biologico-radiological nomogram that can be accurately and noninvasively used for the individualized differentiation SCC from ADC in NSCLC, thereby assisting in clinical decision making for precision treatment.

scholarly journals Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

1996 ◽  
Vol 88 (20) ◽  
pp. 1456-1466 ◽  
Author(s):  
D. F. Hayes ◽  
R. C. Bast ◽  
C. E. Desch ◽  
H. Fritsche ◽  
N. E. Kemeny ◽  
...  
Keyword(s):  
Tumor Marker ◽  
Tumor Markers ◽  
Clinical Utility ◽  
Grading System ◽  
System A

The Clinical Utility of Tumor Markers

2009 ◽  
Vol 40 (2) ◽  
pp. 99-103 ◽  
Author(s):  
Beverly Handy
Keyword(s):  
Tumor Markers ◽  
Clinical Utility

Clinical utility of determining tumor markers in patients with signs and symptoms of cancer

2015 ◽  
Vol 53 (3) ◽  
Author(s):  
Jaume Trapé ◽  
Maria Sala ◽  
Fina Franquesa ◽  
Josep M. Ordeig ◽  
Josep M. Soler-Bel ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Clinical Utility ◽  
Hepatic Dysfunction ◽  
Total Bilirubin ◽  
Signs And Symptoms ◽  
Final Diagnosis ◽  
Wasting Syndrome ◽  
Group A ◽  
Group B

AbstractDiagnosing patients with signs or symptoms suggestive of cancer is difficult. Serum tumor markers (TM) may be useful, but it is known that a range of pathologies other than cancer can increase their concentrations and so TM data must be interpreted with caution. The aim of this study is to determine the diagnostic accuracy of TMs in patients with signs or symptoms of cancer.We prospectively studied 234 patients seen at rapid diagnostic units who presented signs or symptoms suggestive of cancer. Ninety patients had wasting syndrome, 74 had pulmonary symptoms and 70 other presentations. CYFRA21-1, CEA, CA19-9, total bilirubin and creatinine were determined. The final diagnosis was obtained after 6 months’ follow-up. Patients were classified according to the absence (group A) or presence (group B) of abnormal bilirubin or creatinine.Of the 234 patients studied, 103 (44.0%) had tumors diagnosed. Cut-off points for each TM were calculated for a specificity of 100%. For the total group, the values were CYFRA21-1, 15 μg/L, CEA, 43.8 μg/L and CA19-9, 7428 KU/L, with an overall sensitivity of 46.6%. For group A (n=142), the following cut-off points were established: CYFRA21-1, 7.8 μg/L, CEA, 13.8 μg/L and CA19-9, 101 KU/L, obtaining a sensitivity of 68.6%. For group B (n=92), the values were the same as for the whole group, and a sensitivity of 42.4% was achieved.We conclude that TMs can aid diagnosis in these patients with signs or symptoms suggestive of cancer. Their sensitivity can be improved by using different cut-off points in the presence and absence of renal and hepatic dysfunction.

Clinical Utility of Oncofetal and Proteins and Hormones as Tumor Markers

1986 ◽  
Vol 70 (6) ◽  
pp. 1295-1306 ◽  
Author(s):  
Patricia E. Garrett ◽  
Sanford R. Kurtz
Keyword(s):  
Tumor Markers ◽  
Clinical Utility
Sign in / Sign up

Export Citation Format

Share Document